{
    "title": "A meta-analysis of effects of vitamin E supplementation alone and in combination with omega-3 or magnesium on polycystic ovary syndrome",
    "journal": "Scientific Reports",
    "publication_date": "2022",
    "abstract": "Vitamin E supplementation might have favorable effects on risk factors of polycystic ovary syndrome (PCOS). This systematic review and meta-analysis aimed to summarize the effects of vitamin E supplementation or vitamin E in combination with omega-3 or magnesium on PCOS. PubMed, Scopus, ISI Web of Science, Cochrane, Embase electronic databases, and Google scholar were searched for all available articles up to September 2022. Randomized controlled trials (RCTs) that examined the effect of vitamin E supplementation or vitamin E in combination with omega-3 or magnesium on lipid and glycemic profiles, anthropometric measurements, biomarkers of inflammation and oxidative stress, hormonal profile, and hirsutism score in patients with PCOS were included. Ten RCTs (with 504 participants) fulfilled the eligible criteria. Vitamin E supplementation or vitamin E in combination with omega-3 or magnesium in comparison to placebo could significantly reduce serum levels of TG (weighted mean difference: \u2212\u00a018.27\u00a0mg/dL, 95% CI \u2212\u00a034.68 to \u2212\u00a01.87), VLDL (\u2212\u00a05.88\u00a0mg/dL, 95% CI \u2212\u00a08.08 to \u2212\u00a03.68), LDL-c (\u2212\u00a012.84\u00a0mg/dL, 95% CI \u2212\u00a022.15 to \u2212\u00a03.52), TC (\u2212\u00a016.30\u00a0mg/dL, 95% CI \u2212\u00a029.74 to \u2212\u00a02.86), TC/HDL-c ratio (\u2212\u00a00.52, 95% CI \u2212\u00a00.87 to \u2212\u00a00.18), hs-CRP (\u2212\u00a00.60\u00a0ng/mL, 95% CI \u2212\u00a00.77 to \u2212\u00a00.44), hirsutism score (\u2212\u00a00.33, 95% CI \u2212\u00a00.65 to \u2212\u00a00.02) and significantly increase nitric oxide levels (2.79\u00a0\u00b5mol/L, 95% CI 0.79\u20134.79). No significant effect was found on HDL-c, glycemic indices, hormonal profile, anthropometric measurements, and other biomarkers of inflammation or oxidative stress. This meta-analysis highlights the potential anti-hyperlipidemic, anti-oxidant, and anti-inflammatory properties of vitamin E supplementation alone or in combination with omega-3 or magnesium on PCOS patients.",
    "body": "Introduction  Polycystic ovary syndrome (PCOS) is one of the most common and complex endocrine disturbances estimated to affect 6 to 25% of women in reproductive age 1 , 2 . PCOS is characterized by menstrual dysfunction, hyperandrogenism, ovulatory dysfunction, and subfertility 3 . Low-grade inflammation, including increased C-reactive protein (CRP), tumor necrosis factor-\u03b1 (TNF-\u03b1), and interleukin-6 (IL-6) plays a role in pathophysiology of PCOS 4 . Hyperinsulinemia and insulin resistance seem to be predominant features of PCOS, along with dysfunction of the hypothalamic-pituitary axis, which result in hormonal alterations, including increased serum luteinizing hormone (LH)/ follicle-stimulating hormone (FSH) ratio and circulating androgens. Dyslipidemia is also present in 70% of PCOS patients 5 , 6 . Thus, this syndrome can result in obesity and metabolic disorders like dyslipidemia, insulin resistance and increased hormonal and inflammatory disorders, and oxidative stress. Long-term consequences of PCOS are type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD), hypertension, cancer, and psychological problems 7 \u2013 9 . Therefore, the adverse effects of PCOS could threaten the quality of life in women 10 .  The etiology of PCOS is unknown, but genetics along with environmental and lifestyle factors have been significantly implied in the development of the syndrome 11 , 12 . Lifestyle changes and nutritional interventions along with weight loss are successful treatments for patients with PCOS 1 . Dietary factors like anti-inflammatory foods may have a significant role in improving metabolic disorders of the syndrome 10 . Recently, there was an increasing attention to the health benefits of vitamin E. Vitamin E could possess anti-inflammatory, anti-oxidative, anti-hyperglycemic, anti-hypertensive, anti-hypercholesterolemic, and anti-obesity properties 13 .  Several clinical trials have examined the effect of vitamin E supplementation alone or in combination with omega-3 or magnesium on improving metabolic and hormonal profile, inflammatory markers, oxidative stress, hirsutism, and anthropometric parameters in PCOS patients, but controversial results have been reported 2 , 14 \u2013 23 . Some trials showed that vitamin E supplementation alone or along with omega-3 could significantly improve total and free testosterone in PCOS patients 15 , 16 . In contrast, others reported that vitamin E and magnesium co-supplementation did not affect serum total testosterone levels 14 . Several studies indicated that vitamin E and magnesium or omega-3 co-supplementation might improve most indicators of lipid profiles in PCOS patients 15 , 17 . However, Izadi et al. suggested that vitamin E supplementation could only lead to a significant decrease in serum TG levels 18 . In addition, Chen et al. showed that short-term supplementation with vitamin E could improve oxidative stress markers such as malondialdehyde (MDA) 19 ; while, other trials suggested that vitamin E supplementation along with magnesium did not affect MDA levels in PCOS patients 14 . To our knowledge, no previous review has systematically summarized the effects of vitamin E supplementation alone or along with omega-3 or magnesium on improvement of the metabolic and hormonal profile, inflammatory markers, oxidative stress, hirsutism, and anthropometric parameters in PCOS. So, we conducted a systematic review and meta-analysis on randomized clinical trials that evaluated the effects of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on PCOS patients.    Materials and methods   Search strategy  A comprehensive literature search was conducted of the MEDLINE (PubMed), Scopus, ISI Web of Science, Cochrane, and Embase electronic databases, as well as Google scholar, up to September 2022, with no limitation in language, time of publication or study location. The following combination of search terms was used: (\u201cvitamin E\u201d OR tocopherol OR tocotrienol OR \u201cVIT E\u201d OR \u201calpha-Tocopherol\u201d OR \u201cbeta-Tocopherol\u201d OR \u201cgamma-Tocopherol\u201d OR magnesium OR omega-3 OR \u201cn-3 fatty acid\u201d OR W-3 OR EPA OR DHA OR ALA OR \u201cfish oil\u201d OR \u201calpha-Linolenic Acid\u201d OR \u201cDocosahexaenoic Acids\u201d OR \u201cEicosapentaenoic Acid\u201d) AND (PCOS OR \u201cpolycystic ovarian syndrome\u201d OR \u201cPolycystic Ovary Syndrome\u201d). Moreover, manual searches of the bibliographies of the relevant investigations were performed to avoid missing any publication. Duplicate citations were removed. The article selection was independently carried out by 2 investigators (H.H. and Z.H.), and any disagreement was resolved by consultation with the principal investigator (P.S.). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline (PRISMA) were followed in the present report. The study protocol was registered at PROSPERO (no. CRD42021256820).    Inclusion and exclusion criteria  Published articles were included in the systematic review and meta-analysis if they met the following criteria: (1) be a randomized controlled trial (RCT); (2) conducted on women with PCOS; (3) supplemented intervention group with vitamin E or vitamin E in combination with omega-3 or magnesium, and control group with placebo; and (4) reported means and standard deviations (SDs) or standard errors (SEs) of lipid profile (TG, very low-density lipoprotein-cholesterol (VLDL), LDL-c, HDL-c, TC and TC/HDL-c ratio), glycemic indices (fasting blood sugar (FBS), insulin, homeostasis model assessment-estimated insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI)), hormonal parameters (total testosterone, serum luteinizing hormone (LH), follicle stimulating hormone (FSH), sex hormone-binding globulin (SHB) and free androgen index (FAI)), biomarkers of inflammation and oxidative stress (total antioxidant capacity (TAC), glutathione (GSH), MDA, high sensitive C-reactive protein (hs-CRP) and nitric oxide (NO)), anthropometric measurements (weight, body mass index (BMI), waist circumference and metabolic equivalents (METs)), and/or hirsutism score (ferriman\u2013Gallwey (mf-G)), before and after supplementation. Studies were excluded if they did not provide integrated data or did not have an appropriate intervention. Details of more related studies that were excluded from the present review are described in Supplemental Table S1 .    Data extraction  The following data were extracted from the eligible papers: first author\u2019s name, publication year, study location, sample size of each intervention group, age range or mean age, number of participants in each group, study design, duration of intervention, dosage of vitamin E supplementation or vitamin E in combination with omega-3 or magnesium, type of intervention, and mean\u2009\u00b1\u2009SD/SE of lipid and glycemic profiles, anthropometric measurements, biomarkers of inflammation and oxidative stress, hormonal profile and hirsutism score at baseline and the end of the intervention, matching of two intervention groups and final adjustments in the analysis. This process was independently performed by two investigators (H.H. and Z.H.). The principal researcher (P.S.) supervised data extraction. All reported SEs were converted to SDs using the appropriate formula. When the concentration of an indicator was reported in different units among included studies, we converted them to the most frequently used unit.    Quality assessment of studies  Revised Cochrane Collaboration's tools (RoB2.0) was used to assess the quality of each included RCT 24 . According to this tool, each trial was assessed based on the following domains: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other sources of bias. For each study, two authors have independently evaluated the risk of bias as low risk, high risk, and some concern for each domain. Finally, the overall quality of the study was categorized into: low risk, if the study was judged to be at low risk of bias for all domains; high risk, if the study was judged to be at high risk of bias in at least one domain; some concern, if the study was judged to be at some concern in at least one domain 24 .    Statistical analysis  To pool the effect of vitamin E supplementation or vitamin E in combination with omega-3 or magnesium supplementation on women with PCOS, the mean change and its standard deviation for intervention and control groups were extracted or calculated. Then, weighted mean differences (WMDs) with 95% confidence intervals (CIs) were computed through a random effects model. Between-study heterogeneity was tested by Cochran's Q test and quantified by I 2 statistic. Subgroup analysis and meta-regression were performed to find the source of heterogeneity. Sensitivity analysis was used to explore the influence of a single study on the overall estimate. Publication bias was examined via visual inspection of funnel plots. A formal statistical assessment of funnel plot asymmetry was done using Begg\u2019s and Egger\u2019s tests. All statistical analyses were performed using STATA, version 11.2 (STATA Corp., College Station, TX). P values less than 0.05 were considered as statistically significant.     Results   Selection and identification of studies  Out of the initial 928 studies obtained by electronic and manual searches, 275 articles were excluded as duplicates. First, the title and abstract of the remaining 653 articles were screened, and 639 of them were excluded based on the inclusion criteria. Then, the full text of 14 articles was carefully assessed, and after excluding 4 irrelevant studies, 10 eligible RCTs were included in the present meta-analysis. It should be noted that Izadi et al. have conducted a trial on 43 women with PCOS and reported the results in two papers 16 , 18 ; one of these papers showed the effect of vitamin E supplementation on lipid profile, and the other one reported the impact of vitamin E supplementation on glycemic and hormonal profiles. So, there was no overlapping in outcomes of interest, and we considered these reports as two trials. Finally, 10 RCTs were included in the present meta-analysis. A flow chart describing the systematic search and study selection process is illustrated in Fig. 1 . Figure 1 Flow chart of the systematic search and study selection.     Systematic review  The main characteristics of 10 RCTs included in the systematic review and meta-analysis are described in Table 1 . All eligible RCTs were carried out in Iran, published between 2017 and 2019, and had a sample size ranging from 40 to 68 participants. The mean age of participants in these trials ranged from 18 to 40\u00a0years. Duration of the intervention period varied from 8 to 12\u00a0weeks. In all RCTs, PCOS was defined based on the 2003 Rotterdam criteria. All RCTs had a parallel study design. The intervention group received vitamin E supplement in 3 trials 2 , 16 , 18 , vitamin E plus magnesium in 2 studies 14 , 17 , and vitamin E plus omega-3 in 5 studies 15 , 20 \u2013 23 , while in all studies the control group received placebo. The dose of vitamin E for the intervention group ranged from 400 to 888\u00a0IU/day. Doses of omega-3 and magnesium co-supplemented with vitamin E in RCTs were 1000\u00a0mg/day and 250\u00a0mg/day, respectively. These trials reported the effects of vitamin E supplementation or vitamin E in combination with omega-3 or magnesium supplementation on anthropometric measurements, lipid and glycemic profiles, biomarkers of inflammation and oxidative stress, hormonal profile and hirsutism score. Table 1 The main characteristics of clinical trial studies which were included in the systematic review and meta-analysis. Author, year Country Mean age/age range (year) (intervention/control) No. of participants (intervention/control) Study duration (wk) Control Intervention (content/dose) Outcome Intervention Control Adjustment or matching Quality score 1 Before (mean\u2009\u00b1\u2009SD) After (mean\u2009\u00b1\u2009SD) Change (SD/SE/95% CI) Before (mean\u2009\u00b1\u2009SD) After (mean\u2009\u00b1\u2009SD) Change (SD/SE/95% CI) Jamilian, 2018 Iran 18\u201340 (22.3\u2009\u00b1\u20094.7/24.4\u2009\u00b1\u20094.7 ) 40 (20/20) 12 Placebo (paraffin) 1000\u00a0mg omega-3 fatty acids plus 400\u00a0IU vitamin E supplements Anthropometric measurements Weight(kg) 73.6\u2009\u00b1\u200911.7 72.7\u2009\u00b1\u200911.8 \u2212\u20090.9\u2009\u00b1\u20091.5 69.8\u2009\u00b1\u200917.1 69.4\u2009\u00b1\u200916.9 \u2212\u20090.4\u2009\u00b1\u20091.1 Matched for age and BMI 6 BMI(kg/m 2 ) 28.8\u2009\u00b1\u20095.1 28.5\u2009\u00b1\u20095.1 \u2212\u20090.3\u2009\u00b1\u20090.6 26.5\u2009\u00b1\u20095.9 26.3\u2009\u00b1\u20095.8 \u2212\u20090.2\u2009\u00b1\u20090.4 HC (cm) 102.1\u2009\u00b1\u200912.1 101.7\u2009\u00b1\u200913.1 \u2212\u20090.4\u2009\u00b1\u20090.5 98.7\u2009\u00b1\u200912.6 98.6\u2009\u00b1\u200912.4 \u2212\u20090.1\u2009\u00b1\u20091.0 WC (cm) 90.0\u2009\u00b1\u200912.7 89.6\u2009\u00b1\u200912.6 \u2212\u20090.4\u2009\u00b1\u20090.5 87.1\u2009\u00b1\u200912.4 86.9\u2009\u00b1\u200912.2 \u2212\u20090.2\u2009\u00b1\u20090.6 METs 27.9\u2009\u00b1\u20092.1 28.0\u2009\u00b1\u20092.2 0.1\u2009\u00b1\u20090.9 27.1\u2009\u00b1\u20091.9 27.2\u2009\u00b1\u20092.1 0.1\u2009\u00b1\u20090.6 Hirsutism mF-G 15.8\u2009\u00b1\u20094.0 15.1\u2009\u00b1\u20093.6 \u2212\u20090.7\u2009\u00b1\u20090.9 14.1\u2009\u00b1\u20093.6 13.9\u2009\u00b1\u20093.3 \u2212\u20090.2\u2009\u00b1\u20090.5 Rahmani, 2017 Iran 18\u201340 (24.9\u2009\u00b1\u20095.5/26.6\u2009\u00b1\u20095.6 ) 68 (34/34) 12 Placebo 1000\u00a0mg omega-3 fatty acids from flaxseed oil containing 400\u00a0mg \u03b1-linolenic acid plus 400\u00a0IU vitamin E supplements Anthropometric measurements Weight(kg) 74.1\u2009\u00b1\u200910.7 73.8\u2009\u00b1\u200910.8 \u2212\u20090.3\u2009\u00b1\u20091.1 77.6\u2009\u00b1\u200918.2 77.4\u2009\u00b1\u200918.3 \u2212\u20090.2\u2009\u00b1\u20091.1 Matched for age and phenotypes A and D of PCOS 7 BMI(kg/m 2 ) 28.4\u2009\u00b1\u20094.4 28.2\u2009\u00b1\u20094.6 \u2212\u20090.1\u2009\u00b1\u20090.4 29.0\u2009\u00b1\u20096.5 29.0\u2009\u00b1\u20096.5 \u2212\u20090.1\u2009\u00b1\u20090.4 METs 29.4\u2009\u00b1\u20092.5 29.5\u2009\u00b1\u20092.5 0.1\u2009\u00b1\u20090.8 28.9\u2009\u00b1\u20092.3 28.8\u2009\u00b1\u20092.3 \u2212\u20090.1\u2009\u00b1\u20090.8 Hormonal profile FSH (IU/L) 7.3\u2009\u00b1\u20092.5 7.2\u2009\u00b1\u20092.5 \u2212\u20090.4\u2009\u00b1\u20090.5* 7.9\u2009\u00b1\u20092.8 8.1\u2009\u00b1\u20093.2 0.5\u2009\u00b1\u20090.5* Adjusted for baseline values, age and BMI at baseline LH (IU/L) 11.0\u2009\u00b1\u20098.0 10.5\u2009\u00b1\u20098.9 \u2212\u20091.2\u2009\u00b1\u20091.4* 13.5\u2009\u00b1\u200913.3 11.4\u2009\u00b1\u20097.7 \u2212\u20091.5\u2009\u00b1\u20090.5* oxidative stress TAC (mmol/L) 860.5\u2009\u00b1\u2009101.0 949.9\u2009\u00b1\u2009119.3 60.3\u2009\u00b1\u200919.1* 969.5\u2009\u00b1\u200985.3 975.4\u2009\u00b1\u200998.0 35\u2009\u00b1\u200919.2* GSH (\u00b5mol/L) 525.3\u2009\u00b1\u200984.1 544.8\u2009\u00b1\u200981.3 21.7\u2009\u00b1\u20098.7* 511.8\u2009\u00b1\u200969.1 555.2\u2009\u00b1\u200962.4 41.1\u2009\u00b1\u20098.7* MDA (\u00b5mol/L) 2.9\u2009\u00b1\u20090.6 2.5\u2009\u00b1\u20090.6 \u2212\u20090.2\u2009\u00b1\u20090.1* 2.2\u2009\u00b1\u20090.5 2.2\u2009\u00b1\u20090.5 \u2212\u20090.2\u2009\u00b1\u20090.1* Biochemical profile TG (mg/dL) 122.7\u2009\u00b1\u200961.7 100.6\u2009\u00b1\u200954.0 \u2212\u200921.9\u2009\u00b1\u20094* 120.6\u2009\u00b1\u200959.4 128.3\u2009\u00b1\u200972.6 7.5\u2009\u00b1\u20094* VLDL-C (mg/dL) 24.5\u2009\u00b1\u200912.3 20.1\u2009\u00b1\u200910.8 \u2212\u20094.4\u2009\u00b1\u20090.8* 24.1\u2009\u00b1\u200911.9 25.7\u2009\u00b1\u200914.5 1.5\u2009\u00b1\u20090.8* TC(mg/dL) 181.8\u2009\u00b1\u200928.0 161.5\u2009\u00b1\u200931.4 \u2212\u200918.1\u2009\u00b1\u20093.8* 166.4\u2009\u00b1\u200929.2 178.6\u2009\u00b1\u200929.9 10\u2009\u00b1\u20093.8* LDL-c (mg/dL) 111.1\u2009\u00b1\u200926.5 94.4\u2009\u00b1\u200929.8 \u2212\u200913.3\u2009\u00b1\u20093.7* 92.9\u2009\u00b1\u200925.5 104.8\u2009\u00b1\u200926.3 8.5\u2009\u00b1\u20093.7* HDL-C (mg/dL) 46.2\u2009\u00b1\u200910.0 47.0\u2009\u00b1\u20099.5 0.2\u2009\u00b1\u20090.8* 49.4\u2009\u00b1\u20098.1 48.1\u2009\u00b1\u20099.3 \u2212\u20090.7\u2009\u00b1\u20090.8* TC/HDL-c 4.1\u2009\u00b1\u20091.0 3.6\u2009\u00b1\u20090.9 \u2212\u20090.4\u2009\u00b1\u20090.1* 3.5\u2009\u00b1\u20090.8 3.9\u2009\u00b1\u20091.1 0.3\u2009\u00b1\u20090.1* Ebrahimi, 2017 Iran 18\u201340 (23.8\u2009\u00b1\u20094.6/25.2\u2009\u00b1\u20095.2 ) 68 (34/34) 12 Placebo 1000\u00a0mg omega-3 fatty acids from flaxseed oil containing 400\u00a0mg\u2002\u03b1-Linolenic\u2002acid\u2002plus\u2002400\u00a0IU\u2002vitamin\u2002E\u2002supplements Anthropometric measurements Weight (kg) 72.4\u2009\u00b1\u200910.7 71.9\u2009\u00b1\u200910.7 0 \u2212\u20090.5\u2009\u00b1\u20091.3 75.1\u2009\u00b1\u200918.2 74.8\u2009\u00b1\u200918.3 \u2212\u20090.3\u2009\u00b1\u20091.1 Matched for age, BMI and phenotypes A and D of PCOS 7 BMI(kg/m 2 ) 28.0\u2009\u00b1\u20094.3 27.8\u2009\u00b1\u20094.3 \u2212\u20090.2\u2009\u00b1\u20090.5 28.5\u2009\u00b1\u20096.6 28.3\u2009\u00b1\u20096.7 \u2212\u20090.2\u2009\u00b1\u20090.4 METs 27.0\u2009\u00b1\u20092.3 27.0\u2009\u00b1\u20092.4 0.02\u2009\u00b1\u20090.7 26.8\u2009\u00b1\u20092.1 26.7\u2009\u00b1\u20092.2 \u2212\u20090.1\u2009\u00b1\u20090.7 Biochemical profile FPG(mg/dL) 90.2\u2009\u00b1\u200910.2 87.0\u2009\u00b1\u20098.6 \u2212\u20093.8\u2009\u00b1\u20091.1* 94.8\u2009\u00b1\u20097.4 94.1\u2009\u00b1\u20099.1 \u2212\u20090.05\u2009\u00b1\u20091.1* Adjusted for baseline values, age and BMI at baseline Insulin\u2002(\u03bcIU/mL) 10.8\u2009\u00b1\u20094.8 9.8\u2009\u00b1\u20094.9 \u2212\u20090.8\u2009\u00b1\u20090.9* 9.8\u2009\u00b1\u20095.7 12.5\u2009\u00b1\u20096.6 2.5\u2009\u00b1\u20090.9* HOMA-IR 2.4\u2009\u00b1\u20091.2 2.2\u2009\u00b1\u20091.2 \u2212\u20090.2\u2009\u00b1\u20090.2* 2.3\u2009\u00b1\u20091.4 2.9\u2009\u00b1\u20091.6 0.6\u2009\u00b1\u20090.2* HOMA-B 39.7\u2009\u00b1\u200918.6 35.4\u2009\u00b1\u200919.1 \u2212\u20093.0\u2009\u00b1\u20093.3* 33.7\u2009\u00b1\u200921.4 44.1\u2009\u00b1\u200925.4 9.2\u2009\u00b1\u20093.3* QUICKI 0.34\u2009\u00b1\u20090.02 0.34\u2009\u00b1\u20090.02 0.002\u2009\u00b1\u20090.005* 0.35\u2009\u00b1\u20090.04 0.33\u2009\u00b1\u20090.02 \u2212\u20090.01\u2009\u00b1\u20090.005* Hirsutism mF-G 13.6\u2009\u00b1\u20093.7 13.3\u2009\u00b1\u20093.7 \u2212\u20090.4\u2009\u00b1\u20090.2* 12.2\u2009\u00b1\u20093.5 12.0\u2009\u00b1\u20093.4 \u2212\u20090.3\u2009\u00b1\u20090.2* Hormonal profile Total\u2002testosterone\u2002(ng/mL) 1.2\u2009\u00b1\u20090.9 0.7\u2009\u00b1\u20090.6 \u2212\u20090.4\u2009\u00b1\u20090.08* 1.1\u2009\u00b1\u20090.6 1.0\u2009\u00b1\u20090.6 \u2212\u20090.06\u2009\u00b1\u20090.08* 7 Free\u2002testosterone\u2002(pg/mL) 4.5\u2009\u00b1\u20093.2 3.3\u2009\u00b1\u20092.4 \u2212\u20091.1\u2009\u00b1\u20090.3* 3.9\u2009\u00b1\u20092.7 3.7\u2009\u00b1\u20092.3 \u2212\u20090.4\u2009\u00b1\u20090.3* SHBG (nmol/L) 37.5\u2009\u00b1\u200915.9 44.1\u2009\u00b1\u200921.3 6.9\u2009\u00b1\u20092.4* 39.1\u2009\u00b1\u200915.0 44.9\u2009\u00b1\u200916.9 5.5\u2009\u00b1\u20092.4* FAI 0.14\u2009\u00b1\u20090.13 0.09\u2009\u00b1\u20090.11 \u2212\u20090.04\u2009\u00b1\u20090.01* 0.12\u2009\u00b1\u20090.17 0.08\u2009\u00b1\u20090.05 \u2212\u20090.04\u2009\u00b1\u20090.01* DHEAS 4.5\u2009\u00b1\u20092.3 3.5\u2009\u00b1\u20092.0 \u2212\u20091.2\u2009\u00b1\u20090.2* 5.2\u2009\u00b1\u20091.9 4.3\u2009\u00b1\u20091.5 \u2212\u20090.7\u2009\u00b1\u20090.2* Izadi, 2019 Iran 20\u201340 (27.18\u2009\u00b1\u20095.77/ 26.0\u2009\u00b1\u20094.53) 43 (22/21) 8 Placebo 400\u00a0IU\u2002vitamin\u2002E Anthropometric measurements BMI(kg/m 2 ) 29.28\u2009\u00b1\u20094.24 28.92\u2009\u00b1\u20094.23 \u20120.37 (\u20120.60, \u20120.14)** 28.73\u2009\u00b1\u20093.39 28.74\u2009\u00b1\u20092.9 0.01 (\u20120.23, 0.25)** \u2013 7 WC (cm) 95.00\u2009\u00b1\u200910.82 92.18\u2009\u00b1\u200910.94 \u20122.81, (\u20123.47, \u20122.15)** 89.33\u2009\u00b1\u20097.97 88.43\u2009\u00b1\u20098.04 \u20120.89, (\u20121.57, \u20120.21)** Biochemical profile TG (mg/dL) 111.68\u2009\u00b1\u200944.41 105.18\u2009\u00b1\u20098.22 \u2212\u20096.48 (\u2212\u20099.31,\u2009\u2212\u20093.66)** 112.86\u2009\u00b1\u200942.27 112.09\u2009\u00b1\u20099.09 \u2212\u20090.99 (\u2212\u20093.89, 1.90)** Adjusted for baseline levels, age, physical activity, dietary intake of energy and vitamin E TC (mg/dL) 163.41\u2009\u00b1\u200921.86 159.00\u2009\u00b1\u200918.96 \u2212\u20094.07 (\u2212\u20099.14, 1.00)** 157.43\u2009\u00b1\u200918.46 159.67\u2009\u00b1\u200922.87 2.37 (\u2212\u20092.84, 7.57)** LDL-C (mg/dL) 82.53\u2009\u00b1\u200920.51 78.10\u2009\u00b1\u200919.83 \u2212\u20094.02 (\u2212\u20099.60, 1.54)** 79.57\u2009\u00b1\u200924.17 82.53\u2009\u00b1\u200922.84 3.07 (\u2212\u20092.64, 8.78)** HDL-C (mg/dL) 58.54\u2009\u00b1\u20099.21 59.86\u2009\u00b1\u20098.45 1.24 (\u2212\u20090.56, 3.05)** 55.28\u2009\u00b1\u200911.94 54.71\u2009\u00b1\u20099.81 \u2212\u20090.5 (\u2212\u20092.36, 1.35)** Non-HDL-C (mg/dL) 104.86\u2009\u00b1\u200922.29 99.14\u2009\u00b1\u200919.78 \u2212\u20095.32 (\u2212\u200910.94, 0.31)** 102.14\u2009\u00b1\u200924.39 104.95\u2009\u00b1\u200924.79 2.87 (\u2212\u20092.90, 8.64)** Jamilian, 2019 Iran 18\u201340 (29.2\u2009\u00b1\u20097.2/28.3\u2009\u00b1\u20093.8 ) 60 (30/30) 12w Placebo 250\u00a0mg/day magnesium plus 400\u00a0mg/ day vitamin E supplements Anthropometrics measurements Weight(kg) 66.7\u2009\u00b1\u20099.5 66.6\u2009\u00b1\u20099.5 \u20130.1\u2009\u00b1\u20090.3 67.8\u2009\u00b1\u200910.9 67.7\u2009\u00b1\u200911.1 \u20130.1\u2009\u00b1\u20090.8 \u2013 7 BMI(kg/m 2 ) 25.5\u2009\u00b1\u20093.5 25.5\u2009\u00b1\u20093.3 \u20130.03\u2009\u00b1\u20090.1 26.0\u2009\u00b1\u20094.7 26.0\u2009\u00b1\u20094.7 \u20130.05\u2009\u00b1\u20090.3 Biochemical profile FPG(mg/dl) 92.1\u2009\u00b1\u200912.2 90.9\u2009\u00b1\u200911.9 \u20131.5\u2009\u00b1\u20091.0* 93.7\u2009\u00b1\u20095.8 94.4\u2009\u00b1\u20096.5 1.0\u2009\u00b1\u20091.0* Adjusted for baseline values\u2009+\u2009age and baseline BMI TG (mg/dl) 125.0\u2009\u00b1\u200953.0 110.0\u2009\u00b1\u200955.0 \u2212\u200915.1\u2009\u00b1\u20094.4* 128.1\u2009\u00b1\u200960.6 134.7\u2009\u00b1\u200968.9 6.8\u2009\u00b1\u20094.4* VLDL-C (mg/dl) 25.0\u2009\u00b1\u200910.6 22.0\u2009\u00b1\u200911.0 \u20133.0\u2009\u00b1\u20099.9* 25.6\u2009\u00b1\u200912.1 26.9\u2009\u00b1\u200913.8 1.3\u2009\u00b1\u20090.9* TC(mg/dl) 181.6\u2009\u00b1\u200940.4 174.5\u2009\u00b1\u200932.2 \u20137.2\u2009\u00b1\u20094.4* 185.0\u2009\u00b1\u200934.4 193.2\u2009\u00b1\u200933.7 8.3\u2009\u00b1\u20094.4* LDL-C (mg/dl) 104.5\u2009\u00b1\u200936.0 101.4\u2009\u00b1\u200930.4 \u20132.7\u2009\u00b1\u20094.6* 106.2\u2009\u00b1\u200937.1 114.2\u2009\u00b1\u200938.9 7.6\u2009\u00b1\u20094.6* HDL-C (mg/dl) 52.1\u2009\u00b1\u200910.1 51.1\u2009\u00b1\u20098.6 \u20131.1\u2009\u00b1\u20091.2* 53.1\u2009\u00b1\u20099.3 52.0\u2009\u00b1\u200910.9 \u20131.0\u2009\u00b1\u20091.2* TC/HDL-C ratio \u2013 \u2013 \u20130.05\u2009\u00b1\u20090.1* \u2013 \u2013 0.3\u2009\u00b1\u20090.1* Insulin\u2002(\u03bcIU/mL) 13.4\u2009\u00b1\u20095.8 12.3\u2009\u00b1\u20095.0 \u20131.0\u2009\u00b1\u20090.5* 12.2\u2009\u00b1\u20095.1 13.9\u2009\u00b1\u20094.5 1.5\u2009\u00b1\u20090.5* HOMA-IR 3.0\u2009\u00b1\u20091.4 2.8\u2009\u00b1\u20091.2 \u2212\u20090.2\u2009\u00b1\u20090.1* 2.8\u2009\u00b1\u20091.2 3.2\u2009\u00b1\u20091.1 0.4\u2009\u00b1\u20090.1* QUICKI 0.32\u2009\u00b1\u20090.01 0.33\u2009\u00b1\u20090.01 0.003\u2009\u00b1\u20090.003* 0.33\u2009\u00b1\u20090.02 0.32\u2009\u00b1\u20090.01 \u2212\u20090.008\u2009\u00b1\u20090.003* Izadi, 2019 Iran 20\u201340 (27.18\u2009\u00b1\u20095.77/ 26.0\u2009\u00b1\u20094.53) 43 (22/21) 8 Placebo 400\u00a0IU\u2002vitamin\u2002E Anthropometric measurements Weight (kg) 76.95\u2009\u00b1\u200910.61 75.96\u2009\u00b1\u200910.3 \u2212\u20091.33 (\u2212\u20090.4 to 2.29)** 73.23\u2009\u00b1\u20097.58 73.29\u2009\u00b1\u20097.3 0.15 (\u2212\u20090.49 to 0.9)** \u2013 7 Biochemical profile FBS(mg/dl) 85.50\u2009\u00b1\u200920.28 81.18\u2009\u00b1\u200910.28 4.32 (0.85 to 7.67)** 17.95\u2009\u00b1\u20099.25 80.57\u2009\u00b1\u20098.96 \u2212\u20090.10 (\u2212\u20093.69 to 3.48)** Adjusted for baseline values, age, BMI, and physical activity Insulin\u2002(mIU/L) 13.72\u2009\u00b1\u20095.92 11.44\u2009\u00b1\u20094.57 2.26 (0.36 to 4.16)** 13.47\u2009\u00b1\u20099.73 12.47\u2009\u00b1\u20097.73 0.89 (1.14 to 2.78)** HOMA-IR 2.80\u2009\u00b1\u20091.17 2.35\u2009\u00b1\u20091.01 0.45 (0.02 to 0.87)** 2.73\u2009\u00b1\u20092.12 2.55\u2009\u00b1\u20091.70 0.16 (\u2212\u20090.28 to 0.60)** Hormonal profile Total\u2002testosterone\u2002(ng/ml) 1.16\u2009\u00b1\u20090.40 0.84\u2009\u00b1\u20090.23 0.32 (0.17 to 0.46)** 1.33\u2009\u00b1\u20090.35 1.47\u2009\u00b1\u20090.39 \u2212\u20090.13 (\u2212\u20090.28 to 0.02)** SHBG 38.00 (25.32 to 72.50)*** 54.10 (31.50 to 66.20)*** \u2212\u20095.93 (\u2212\u200916.08 to 4.23)** 42.30 (25.20 to 56.80)*** 40.80 (31.00 to 44.50)*** 1.05 (\u2212\u20099.43 to 11.52)** FAI 3.08 (1.57 to 8.13)*** 1.66 (1.14 to 2.92)*** 1.39 (0.47 to 2.32)** 2.80 (2.02 to 4.99)*** 3.53 (2.57 to 5.12)*** 0.42 (\u2212\u20090.91 to 0.99)** LH(mIU/ml) 11.15 (7.30 to 17.05)*** 7.25 (6.35 to 15.00)*** 4.88 (2.72 to 7.4)** 8.40 (5.200 to 17.85)*** 10.80 (6.70 to 17.95)*** \u2212\u20090.49 (\u2212\u20092.72 to 1.73)** FSH (mIU/mL) 5.90 (5.27 to 6.77)*** 5.10 (3.75 to 6.27)*** 0.63 (\u2212\u20090.46 to 1.72)** 7.30 (3.70 to 7.65)*** 5.90 (4.80 to 7.10)*** 0.21 (\u2212\u20090.98 to 1.4)** Progesterone (ng/mL) 1.80\u2009\u00b1\u20090.86 2.46\u2009\u00b1\u20091.02 \u2212\u20090.0 (\u2212\u20091.06 to\u2009\u2212\u20090.27)** 1.62\u2009\u00b1\u20090.99 1.60\u2009\u00b1\u20091.12 \u2212\u20090.02 (\u2212\u20090.45 to 0.41)** Estradiol (pg/mL) 85.45\u2009\u00b1\u200917.79 99.66\u2009\u00b1\u200923.01 \u2212\u200913.92 (\u2212\u200934.25 to 6.42)** 74.43\u2009\u00b1\u200917.95 71.09\u2009\u00b1\u200912.38 1.74 (\u2212\u200920.36 to 23.85)** Talari, 2018 Iran 18\u201340 60 (30/30) 12 Placebo 1000\u00a0mg omega-3 plus 400\u00a0IU vitamin E supplements Inflammatory markers hs-CRP (ng/mL) 2877.9\u2009\u00b1\u20092095.5 2487.3\u2009\u00b1\u20091673.1 \u2212\u2009360.2\u2009\u00b1\u2009140.1 2646.7\u2009\u00b1\u20091492.3 2883.7\u2009\u00b1\u20091488.9 206.6\u2009\u00b1\u2009140.1 Adjusted for baseline values, age, BMI at baseline 6 NO(\u03bcmol/L) 49.6\u2009\u00b1\u20092.3 51.3\u2009\u00b1\u20094.7 1.8\u2009\u00b1\u20090.7 46.0\u2009\u00b1\u20096.0 46.1\u2009\u00b1\u20095.9 \u2212\u20090.05\u2009\u00b1\u20090.7 Shokrpour , 2019 Iran 18\u201340 (27.2\u2009\u00b1\u20097.1/26.0\u2009\u00b1\u20093.7) 60 (30/30) 12w Placebo 250\u00a0mg/day magnesium plus 400\u00a0mg/day vitamin E supplements Anthropometric measurements Weight (kg) 69.4\u2009\u00b1\u200910.7 69.2\u2009\u00b1\u200910.6 \u2212\u20090.2\u2009\u00b1\u20090.3 70.9\u2009\u00b1\u200910.3 70.7\u2009\u00b1\u200910.4 \u2212\u20090.1\u2009\u00b1\u20090.6 Matched for age and BMI 7 BMI(kg/m 2 ) 27.1\u2009\u00b1\u20094.2 27.0\u2009\u00b1\u20094.1 \u2212\u20090.1\u2009\u00b1\u20090.1 27.9\u2009\u00b1\u20094.2 27.8\u2009\u00b1\u20094.2 \u2212\u20090.1\u2009\u00b1\u20090.2 Hirsutism mF-G 14.9\u2009\u00b1\u20092.9 14.6\u2009\u00b1\u20092.5 \u2013 13.8\u2009\u00b1\u20093.8 13.8\u2009\u00b1\u20093.8 \u2013 \u2013 Inflammatory markers hs-CRP (ng/mL) 3.7\u2009\u00b1\u20091.9 3.1\u2009\u00b1\u20091.7 \u2013 3.5\u2009\u00b1\u20091.5 3.7\u2009\u00b1\u20091.5 \u2013 NO(\u03bcmol/L) 34.4\u2009\u00b1\u20092.3 38.7\u2009\u00b1\u20094.0 \u2013 36.6\u2009\u00b1\u20095.6 37.0\u2009\u00b1\u20095.8 \u2013 Oxidative stress TAC (mmol/l) 522.4\u2009\u00b1\u200930.6 590.7\u2009\u00b1\u200952.2 \u2013 513.7\u2009\u00b1\u200981.7 514.5\u2009\u00b1\u200977.3 \u2013 GSH (\u03bcmol/L) 508.1\u2009\u00b1\u200969.1 519.4\u2009\u00b1\u200947.7 \u2013 481.1\u2009\u00b1\u2009101.2 483.8\u2009\u00b1\u200994.2 \u2013 MDA (\u03bcmol/L) 2.7\u2009\u00b1\u20090.2 2.6\u2009\u00b1\u20090.2 \u2013 2.4\u2009\u00b1\u20090.5 2.5\u2009\u00b1\u20090.5 \u2013 Hormonal profile Total\u2002testosterone\u2002(ng/ml) 1.4\u2009\u00b1\u20090.8 1.3\u2009\u00b1\u20090.7 \u2013 1.2\u2009\u00b1\u20090.5 1.2\u2009\u00b1\u20090.6 \u2013 SHBG )nmol/l) 51.4\u2009\u00b1\u200926.4 62.9\u2009\u00b1\u200936.3 \u2013 48.5\u2009\u00b1\u200915.1 49.2\u2009\u00b1\u200915.2 \u2013 FAI 0.15\u2009\u00b1\u20090.16 0.11\u2009\u00b1\u20090.11 \u2013 0.09\u2009\u00b1\u20090.05 0.09\u2009\u00b1\u20090.05 \u2013 Sadeghi, 2019 Iran 18\u201340 (26.67\u2009\u00b1\u20093.35 /26.98\u2009\u00b1\u20093.78) 62 (32/30) 8w Placebo 2\u00a0g of omega-3 plus 400\u00a0IU of vitamin E Oxidative stress TAC(mg/dl) 12.42\u2009\u00b1\u20091.95 13.58\u2009\u00b1\u20092.06 1.15\u2009\u00b1\u20090.93 12.22\u2009\u00b1\u20091.91 12.16\u2009\u00b1\u20091.96 \u2212\u20090.6\u2009\u00b1\u20090.72 \u2013 6 Catalase (IU/L) 10.18\u2009\u00b1\u20091.27 12.01\u2009\u00b1\u20091.26 1.19\u2009\u00b1\u20091.06 11.14\u2009\u00b1\u20091.11 11.26\u2009\u00b1\u20091.15 0.12\u2009\u00b1\u20090.36 GLU (\u03bcmol/L) 10.65\u2009\u00b1\u20092.57 12.15\u2009\u00b1\u20092.66 1.5\u2009\u00b1\u20091.06 10.77\u2009\u00b1\u20092.53 11.00\u2009\u00b1\u20092.65 0.23\u2009\u00b1\u20091.43 MDA (\u03bcmol/L) 1.76\u2009\u00b1\u20090.29 1.42\u2009\u00b1\u20090.26 \u2212\u20090.34\u2009\u00b1\u20090.32 1.38\u2009\u00b1\u20090.26 1.95\u2009\u00b1\u20092.23 0.57\u2009\u00b1\u20092.20 Shirazi, 2019 Iran 20\u201340 (27.18\u2009\u00b1\u20095.77 /26.0\u2009\u00b1\u20094.53) 43 (22/21) 8w Placebo 400\u00a0IU/day vitamin E -as alpha tocopheryl acetate Anthropometric measurements Weight (kg) 76.95\u2009\u00b1\u200910.61 75.96\u2009\u00b1\u200910.3 \u2013 73.23\u2009\u00b1\u20097.58 73.29\u2009\u00b1\u20097.3 \u2013 Matched for age and BMI 7 BMI(kg/m 2 ) 29.45\u2009\u00b1\u20095.35 29.07\u2009\u00b1\u20095.16 \u2013 28.80\u2009\u00b1\u20093.71 28.83\u2009\u00b1\u20093.70 \u2013 BMI body mass index, WC waist circumference, HC hip circumference, METs metabolic equivalents, FBS fasting blood sugar, FPG fasting plasma glucose, HOMA-\u03b2 the homeostasis model assessment-\u03b2 cell function, HOMA-IR the homeostasis model, QUICKI quantitative insulin sensitivity check index, TG triglyceride, HDL-c high density lipoprotein cholesterol, LDL-c low density lipoprotein cholesterol, VLDL-c very low-density lipoprotein-cholesterol, TC TCesterol, TAC total antioxidant capacity, NO nitric oxide, hs-CRP high sensitive C-reactive protein, MDA malondialdehyde, GSH glutathione, LH serum luteinizing hormone, FSH follicle stimulating hormone, FAI free androgen index, SHBG sex hormone-binding globulin, DHEAS dehydroepiandrosterone sulfate, GLU glutathione, mF-G ferriman\u2013Gallwey. 1 According to Cochrane quality score. *SE. ** 95% CI. ***IQR.  In case of sample size of the included RCTs, considering a type one error (\u03b1) of 5% and power of 80 or 90%, along with HOMA-IR, TG, hs-CRP and progesterone as the key outcome variables, sample size for each intervention group was calculated by the use of the proposed formula for parallel clinical trials. In almost all studies, an acceptable sample size was included in the final analysis 2 , 14 \u2013 18 , 20 , 22 , 23 .    Quality of included studies  Details of quality assessment of included articles are presented in Supplemental Table S2 . All eligible RCTs have adequately performed random sequence generation; however, one RCT (10%) was judged as having some concern for allocation concealment 20 . All RCTs have adequately done blinding of participants and personnel and blinding of outcome assessment. One RCT (10%) was judged as high risk of bias for incomplete outcome data 21 , and one RCT (10%) was judged as high risk of bias for selective outcome reporting 22 . All RCTs showed a low risk for other sources of bias. Overall, seven RCTs (70%) were rated as low risk of bias 2 , 14 \u2013 18 , 23 , and two others (20%) were rated as having high certainty of bias 21 , 22 , due to incomplete outcome data and selective outcome reporting and the last RCT (10%) was rated as some concern 20 .    Meta-analysis of the effects of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on lipid profile  The effect of supplementation on lipid profile in PCOS patients was examined in 3 RCTs 17 , 18 , 23 (with 171 subjects). Overall, we found a significant reduction in serum levels of TG (weighted mean difference (WMD): \u2212\u00a018.27\u00a0mg/dL, 95% CI \u2212\u00a034.68 to \u2212\u00a01.87), VLDL (WMD: \u2212\u00a05.88\u00a0mg/dL, 95% CI \u2212\u00a08.08 to \u2212\u00a03.68), LDL-c (WMD: \u2212\u00a012.84\u00a0mg/dL, 95% CI \u2212\u00a022.15 to \u2212\u00a03.52), TC (WMD: \u2212\u00a016.30\u00a0mg/dL, 95% CI \u2212\u00a029.74 to \u2212\u00a02.86) and TC /HDL-c ratio (WMD: \u2212\u00a00.52, 95% CI \u2212\u00a00.87 to \u2212\u00a00.18) after vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation in comparison to placebo, while the observed increase in HDL-c level was not statistically significant (Fig. 2 ). There was a significant heterogeneity between studies in the case of TG (I 2 =\u200990.1%, P\u2009<\u20090.001) and TC (I 2 =\u200982.1%, P\u2009=\u20090.004). To find the source of heterogeneity, meta-regression was conducted based on age and duration of intervention. Between-study heterogeneity was removed after these meta-regressions for age (for TG: \u03b2\u2009=\u2009\u2212\u00a00.008, P\u2009=\u20090.98, I 2 residual\u2009=\u20090.00%; for TC: \u03b2\u2009=\u20090.028, P\u2009=\u20090.94, I 2 residual\u2009=\u20090.00%) and duration of intervention (for TG: \u03b2\u2009=\u2009\u2212\u00a00.187, P\u2009=\u20090.55, I 2 residual\u2009=\u20090.00%; for TC: \u03b2\u2009=\u2009\u2212\u00a00.194, P\u2009=\u20090.63, I 2 residual\u2009=\u20090.00%), although the regression coefficients were not statistically significant. Subgroup analysis could not be performed, due to the small number of eligible trials. Figure 2 Forest plots of the effect of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on lipid profile. If the diamond does not touch the vertical line (or the line of null effect), the overall effect is statistically significant. Significant reductions were found in serum levels of TG (WMD:\u2009\u2212\u200918.27\u00a0mg/dL, 95% CI\u2009\u2212\u200934.68 to\u2009\u2212\u20091.87), VLDL (WMD:\u2009\u2212\u20095.88\u00a0mg/dL, 95% CI\u2009\u2212\u20098.08 to\u2009\u2212\u20093.68), LDL-c (WMD:\u2009\u2212\u200912.84\u00a0mg/dL, 95% CI\u2009\u2212\u200922.15 to\u2009\u2212\u20093.52), TC (WMD:\u2009\u2212\u200916.30\u00a0mg/dL, 95% CI\u2009\u2212\u200929.74 to\u2009\u2212\u20092.86) and TC /HDL-c ratio (WMD:\u2009\u2212\u20090.52, 95% CI\u2009\u2212\u20090.87 to\u2009\u2212\u20090.18) in PCOS patients after vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation in comparison to placebo.     Meta-analysis of the effects of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on biomarkers of inflammation and oxidative stress  A total of 3 RCTs 14 , 21 , 23 with 190 participants were included in this analysis. Meta-analysis could not show any beneficial effect for vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on TAC (WMD: 31.69\u00a0mmol/L, 95% CI \u2212\u00a020.89 to 84.27), GSH (WMD: \u2212\u00a04.53\u00a0\u00b5mol/L, 95% CI \u2212\u00a031.91 to 22.86) and MDA (WMD: \u2212\u00a00.20\u00a0\u00b5mol/L, 95% CI \u2212\u00a00.46 to 0.07). However, a slight but significant decrease in hs-CRP (WMD: \u2212\u00a00.60\u00a0ng/mL, 95% CI \u2212\u00a00.77 to \u2212\u00a00.44) and a significant increase in NO levels (WMD: 2.79\u00a0\u00b5mol/L, 95% CI 0.79\u20134.79) were found (Fig. 3 ). There was a significant heterogeneity among trials in case of TAC (I 2 =\u200996.8%, P\u2009<\u20090.001) and NO (I 2 =\u200990.3%, P\u2009=\u20090.001). For TAC, meta-regression based on age (\u03b2\u2009=\u2009\u2212\u00a00.003, P\u2009=\u20090.98, I 2 residual\u2009=\u20090.00%) and duration of intervention (\u03b2\u2009=\u20090.062, P\u2009=\u20090.71, I 2 residual\u2009=\u20090.00%) removed the observed heterogeneity, although regression coefficients for these covariates were not significant. Figure 3 Forest plots of the effect of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on biomarkers of inflammation and oxidative stress. If the diamond does not touch the vertical line (or the line of null effect), the overall effect is statistically significant. A significant decrease in serum level of hs-CRP (WMD\u2009\u2212\u20090.60\u00a0ng/mL, 95% CI\u2009\u2212\u20090.77 to\u2009\u2212\u20090.44) and a significant increase in the serum level of NO (WMD: 2.79\u00a0\u00b5mol/L, 95% CI 0.79\u20134.79) were found in PCOS patients after vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation in comparison to placebo.     Meta-analysis of the effects of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on glycemic indices  As shown in Fig. 4 , pooling effect sizes from 3 RCTs 15 \u2013 17 with 171 subjects showed a non-significant reduction in FBS (WMD\u2009=\u2009\u2212\u00a01.08\u00a0mg/dL, 95% CI \u2212\u00a05.07 to 2.91), insulin (WMD\u2009=\u2009\u2212\u00a01.47 \u00b5IU/mL, 95% CI \u2212\u00a04.15 to 1.22), HOMA-IR (WMD\u2009=\u2009\u2212\u00a00.40, 95% CI \u2212\u00a00.95 to 0.15) and no change in QUICKI (WMD\u2009=\u20090.01, 95% CI 0.00\u20130.02) in PCOS patients after vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation, as compared to placebo. A significant heterogeneity was found among the studies in case of FBS (I 2 =\u200975.1%, P\u2009=\u20090.018), insulin (I 2 =\u200982.5%, P\u2009=\u20090.003) and HOMA-IR (I 2 =\u200975.9%, P\u2009=\u20090.016). Meta-regression was performed to find the probable effect of age and duration of the intervention (as covariates) on heterogeneity. Findings showed that age (for FBS: \u03b2\u2009=\u20090.079, P\u2009=\u20090.91, I 2 residual\u2009=\u200974.89%; for insulin: \u03b2\u2009=\u20090.101, P\u2009=\u20090.92, I 2 residual\u2009=\u200989.14; for HOMA-IR: \u03b2\u2009=\u20090.601, P\u2009=\u20090.90, I 2 residual\u2009=\u200999.49%) could not significantly explain the observed heterogeneity, but duration of intervention (for FBS: \u03b2\u2009=\u2009\u2212\u00a00.510, P\u2009=\u20090.39, I 2 residual\u2009=\u20090.00%; for insulin: \u03b2\u2009=\u2009\u2212\u00a00.959, P\u2009=\u20090.19, I 2 residual\u2009=\u20090.00%; for HOMA-IR: \u03b2\u2009=\u2009\u2212\u00a03.944, P\u2009=\u20090.12, I 2 residual\u2009=\u200985.81) could resolve the observed heterogeneity for FBS and insulin. Figure 4 Forest plots of the effect of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on glycemic indexes. If the diamond does not touch the vertical line (or the line of null effect), the overall effect is statistically significant. No significant effects of vitamin E supplementation or vitamin E supplementation plus omega-3 or magnesium on glycemic indices were found in PCOS patients.     Meta-analysis of the effects of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on hormonal profile  Effect sizes of 3 eligible RCTs 14 \u2013 16 (with 171 subjects) were pooled; no significant effect for vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation was found [total testosterone (WMD\u2009=\u20090.00\u00a0mg/mL, 95% CI \u2212\u00a00.42 to 0.43), LH (WMD\u2009=\u20092.79 mIU/mL, 95% CI \u2212\u00a02.18 to 7.76), FSH (WMD\u2009=\u2009\u2212\u00a00.30 mIU/mL, 95% CI \u2212\u00a01.59 to 0.99), SHBG (WMD\u2009=\u20093.26\u00a0nmol/L, 95% CI \u2212\u00a05.71 to 12.24) and FAI (WMD\u2009=\u2009\u2212\u00a00.02, 95% CI \u2212\u00a00.06 to 0.03)] (Fig. 5 ). Between-study heterogeneity was significant in case of total testosterone (I 2 =\u200993.2%, P\u2009<\u20090.001), LH (I 2 =\u200981.1%, P\u2009=\u20090.021), SHBG (I 2 =\u200970.5%, P\u2009=\u20090.034) and FAI (I 2 =\u200966.9%, P\u2009=\u20090.049). Meta-regression based on age (for total testosterone: \u03b2\u2009=\u20092.195, P\u2009=\u20090.48, I 2 residual\u2009=\u200999.36%; for SHBG: \u03b2\u2009=\u20090.094, P\u2009=\u20090.85, I 2 residual\u2009=\u20090.00%; for FAI: \u03b2\u2009=\u20090.986, P\u2009=\u20090.71, I 2 residual\u2009=\u200999.98%) and duration of intervention (for total testosterone: \u03b2\u2009=\u2009\u2212\u00a05.448, P\u2009=\u20090.19, I 2 residual\u2009=\u200999.08; for FAI: \u03b2\u2009=\u2009\u2212\u00a03.923, P\u2009=\u20090.11, I 2 residual\u2009=\u200995.63%) could not resolve the observed heterogeneity for total testosterone and FAI, while this analysis removed the observed heterogeneity for SHBG (\u03b2\u2009=\u20090.129, P\u2009=\u20090.79, I 2 residual\u2009=\u20090.00%). Figure 5 Forest plots of the effect of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on hormonal profile. If the diamond does not touch the vertical line (or the line of null effect), the overall effect is statistically significant. No significant effect of vitamin E supplementation or vitamin E plus omega-3 or magnesium supplementation on hormonal profile was found in PCOS patients.     Meta-analysis of the effects of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on anthropometric indices and hirsutism  As illustrated in Supplemental Fig. S1 , vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation had no effect on weight (WMD\u2009=\u2009\u2212\u00a00.12\u00a0kg, 95% CI \u2212\u00a00.28 to 0.05), BMI (WMD\u2009=\u2009\u2212\u00a00.01\u00a0kg/m 2 , 95% CI \u2212\u00a00.07 to 0.05) and waist circumference (WMD\u2009=\u2009\u2212\u00a01.00\u00a0cm, 95% CI \u2212\u00a02.69 to 0.68) in PCOS patients. However, a significant decrease in hirsutism score (WMD\u2009=\u2009\u2212\u00a00.33, 95% CI \u2212\u00a00.65 to \u2212\u00a00.02) was observed among PCOS patients, after vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation as compared to placebo (Supplemental Fig. S2 ). There was no significant heterogeneity between studies in the case of hirsutism score and anthropometric measurements except for waist circumference (I 2 =\u200991.3%, P\u2009=\u20090.001). Due to the small number of RCTs, subgroup analysis or meta-regression could not be performed for waist circumference.    Sensitivity analysis and publication bias  Sensitivity analysis indicated that overall effect sizes for body weight and BMI variables did not substantially change after the elimination of each included study. Sensitivity analysis was not performed for other outcomes, due to the small number of eligible studies. Publication bias was not assessed, since the limited number of effect sizes (<\u200910 per each outcome) rendered the interpretation of the statistical tests unreliable 25 .     Discussion  The current meta-analysis on 10 RCTs with 504 women with PCOS showed that vitamin E supplementation or vitamin E in combination with omega-3 or magnesium could result in significant decreases in lipid profile (TG, TC, LDL-c, VLDL, TC/HDL-c), hs-CRP and hirsutism score and an increase in NO concentration. Vitamin E supplementation or vitamin E, along with omega-3 or magnesium co-supplementation, had no impact on glycemic indices, hormonal profile, other biomarkers of inflammation or oxidative stress, anthropometric measurements, and HDL-c levels. So, the positive effect of vitamin E in PCOS might be independent of weight loss. Our findings highlighted the potential anti-hyperlipidemic, anti-oxidant, and anti-inflammatory properties of vitamin E on PCOS; therefore, this vitamin could be used as an adjunctive therapy for the management of some clinical manifestations and complications of PCOS.  Similar to our findings, a recent meta-analysis on RCTs showed that omega-3 and vitamin E co-supplementation could have beneficial effects on lipid profiles among overweight patients with metabolic syndrome 26 . In another meta-analysis on nine RCTs, omega-3 fatty acid supplementation among PCOS patients could decrease circulating TC, and TG concentrations 10 . Contrary to our findings, a meta-analysis on RCTs showed that vitamin E plus omega-3 fatty acid co-supplementation could reduce VLDL levels, but did not change other lipid indices among subjects with a wide range of metabolic disorders 27 . Also, in a meta-analysis of fifteen RCTs, it was shown that supplementation with tocotrienols did not reduce the concentrations of LDL-c, TC and TG of participants with various clinical conditions, while an increase in HDL-c levels was observed 28 . It is also worth noting that in most previous investigations, the term vitamin E was often synonymously used with \u03b1-tocopherol, while \u03b1-tocopherol is only one of eight natural forms of vitamin E, and new findings have suggested various properties for different forms of vitamin E 29 . In addition, among the investigations included in the present meta-analysis, only one study has specified the form of vitamin E as alpha-tocopheryl acetate 2 . In contrast, other articles did not specify the type of vitamin E supplemented with.  In line with our findings, a recent meta-analysis investigated the effects of vitamin E and omega-3 fatty acids co-supplementation on oxidative stress and inflammation among patients with different diseases and reported a significant decrease in hs-CRP and an increase in NO. Also, no significant effect on MDA or GSH was detected 30 . Similar to our findings, another meta-analysis on eight RCTs showed that vitamin E supplementation had no effect on BMI or insulin resistance (HOMA-IR) among patients with NAFLD; this investigation on NAFLD patients has also shown that vitamin E did not significantly change TG and TC levels, but decreased LDL-c concentrations 31 . Another meta-analysis on fourteen RCTs has documented no effect for vitamin E supplementation on glycemic profile (HbA1c, FBS, and fasting insulin) in patients with T2DM 32 . Although among all these mentioned investigations, the outcomes of interest (including metabolic syndrome, NAFLD, T2DM, and PCOS) were related to insulin resistance, these prior meta-analyses had different study populations, inclusion and exclusion criteria for eligible studies, type and dose of supplementation (vitamin E or omega 3 or vitamin E plus omega 3 co-supplementation), and gender of the study population. So, different methodology aspects led to different findings. More trials are needed to shed light on the effect of vitamin E supplementation on PCOS and other metabolic disorders.  NO is a signaling molecule with a large number of functions in the immune system, the nervous system and apoptosis. NO has additionally a key role in the pathogenesis of inflammation. It has an anti-inflammatory effect under normal physiological situations; whereas, it is considered as a pro-inflammatory mediator that induces inflammation due to overproduction in abnormal conditions 33 . This overproduction of NO as an inflammatory mediator can lead to tissue destruction such as in inflammatory autoimmune diseases. Therefore, NO is a \u2018double-edged sword\u2019 mediator; depending on the concentration, it has pro- or anti-inflammatory effects 33 , 34 . On the other hand, various established non-steroidal anti-inflammatory medications with NO releasing properties have been under intense clinical evaluations in the treatment of inflammatory disorders 35 . In case of women with PCOS, a previous meta-analysis on 12 case\u2013control studies has documented that serum or plasma nitrite levels in patients with this syndrome were lower than healthy controls 36 . The current meta-analysis added the point that vitamin E supplementation alone and in combination with omega-3 or magnesium could significantly increase plasma NO levels in PCOS patients compared to controls. Therefore, this increment in NO concentration can be considered as an anti-inflammatory effect for NO in PCOS patients, although further investigations are required to understand the whole picture of such mediator.  Several mechanisms were suggested for the possible effects of vitamin E supplementation on various metabolic parameters. Chronic exposure to oxidative stress can impair lipid metabolism. Therefore, one hypothesis is that vitamin E improves lipid metabolism by reducing oxidative stress 18 . Anti-inflammatory and antioxidative effects of vitamin E may be explained by suppressing nuclear factor-kappa B (NF-\u03baB) and JAK-signal transducer and activator of transcription 6 (STAT6) or JAK-STAT3 signaling pathways 37 . Moreover, tocotrienols can also downregulate the peroxisome proliferator-activated receptor gamma (PPAR\u03b3) 38 , which is a crucial mediator of adipogenesis 39 . Tocotrienols also possess dazzling lipid-lowering effects, such as downregulating 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase and hence suppressing cholesterol synthesis 38 ; hypocholesterolemic properties of tocotrienols are extended to inhibition of cholesterol absorption in the intestines, as well 40 .  There are several possible mechanisms underlying the association between vitamin E and glucose metabolism. Vitamin E, a fat-soluble antioxidant, can suppress reactive oxygen species (ROS) generation in the pancreas and maintain the structural integrity of pancreatic islets in experimental diabetes 41 . Furthermore, there are some evidence that vitamin E supplementation could inhibit the glycation of hemoglobin 32 , 41 and partially reverse the beta-cell apoptosis caused by oxidative stress 41 , 42 .  The present systematic review and meta-analysis was the first one, to our knowledge, that assessed the effect of vitamin E supplementation or vitamin E in combination with omega-3 or magnesium on women with PCOS. We performed a methodologically strict systematic review of the literature. No evidence of substantial heterogeneity in this meta-analysis was found. However, our study has several limitations. The number of included RCTs was small, so we could not perform stratified analysis based on vitamin E vs. vitamin E plus omega 3 or magnesium supplementation. The included RCTs applied small sample sizes with relatively short intervention periods. Also, most of the eligible articles did not specify the type of vitamin E supplemented with. Finally, dietary intakes of vitamin E, omega-3 and magnesium were not considered in most included trials.  In conclusion, this study demonstrated that vitamin E supplementation or vitamin E in combination with omega-3 or magnesium co-supplementation might have beneficial effects on serum concentrations of TG, TC, LDL-c, VLDL, TC/HDL-c, hs-CRP, NO, and hirsutism score in PCOS patients. No significant effect was found in the case of glycemic indices, hormonal profile, anthropometric measurements, HDL-c levels, and other biomarkers of inflammation or oxidative stress. Additional well-designed clinical trials are needed to affirm these findings.    Supplementary Information    Supplementary Information.",
    "tables": [
        {
            "title": "No Title",
            "content": "Author, year Country Mean age/age range (year) (intervention/control) No. of participants (intervention/control) Study duration (wk) Control Intervention (content/dose) Outcome Intervention Control Adjustment or matching Quality score 1 Before (mean\u2009\u00b1\u2009SD) After (mean\u2009\u00b1\u2009SD) Change (SD/SE/95% CI) Before (mean\u2009\u00b1\u2009SD) After (mean\u2009\u00b1\u2009SD) Change (SD/SE/95% CI) Jamilian, 2018 Iran 18\u201340 (22.3\u2009\u00b1\u20094.7/24.4\u2009\u00b1\u20094.7 ) 40 (20/20) 12 Placebo (paraffin) 1000\u00a0mg omega-3 fatty acids plus 400\u00a0IU vitamin E supplements Anthropometric measurements Weight(kg) 73.6\u2009\u00b1\u200911.7 72.7\u2009\u00b1\u200911.8 \u2212\u20090.9\u2009\u00b1\u20091.5 69.8\u2009\u00b1\u200917.1 69.4\u2009\u00b1\u200916.9 \u2212\u20090.4\u2009\u00b1\u20091.1 Matched for age and BMI 6 BMI(kg/m 2 ) 28.8\u2009\u00b1\u20095.1 28.5\u2009\u00b1\u20095.1 \u2212\u20090.3\u2009\u00b1\u20090.6 26.5\u2009\u00b1\u20095.9 26.3\u2009\u00b1\u20095.8 \u2212\u20090.2\u2009\u00b1\u20090.4 HC (cm) 102.1\u2009\u00b1\u200912.1 101.7\u2009\u00b1\u200913.1 \u2212\u20090.4\u2009\u00b1\u20090.5 98.7\u2009\u00b1\u200912.6 98.6\u2009\u00b1\u200912.4 \u2212\u20090.1\u2009\u00b1\u20091.0 WC (cm) 90.0\u2009\u00b1\u200912.7 89.6\u2009\u00b1\u200912.6 \u2212\u20090.4\u2009\u00b1\u20090.5 87.1\u2009\u00b1\u200912.4 86.9\u2009\u00b1\u200912.2 \u2212\u20090.2\u2009\u00b1\u20090.6 METs 27.9\u2009\u00b1\u20092.1 28.0\u2009\u00b1\u20092.2 0.1\u2009\u00b1\u20090.9 27.1\u2009\u00b1\u20091.9 27.2\u2009\u00b1\u20092.1 0.1\u2009\u00b1\u20090.6 Hirsutism mF-G 15.8\u2009\u00b1\u20094.0 15.1\u2009\u00b1\u20093.6 \u2212\u20090.7\u2009\u00b1\u20090.9 14.1\u2009\u00b1\u20093.6 13.9\u2009\u00b1\u20093.3 \u2212\u20090.2\u2009\u00b1\u20090.5 Rahmani, 2017 Iran 18\u201340 (24.9\u2009\u00b1\u20095.5/26.6\u2009\u00b1\u20095.6 ) 68 (34/34) 12 Placebo 1000\u00a0mg omega-3 fatty acids from flaxseed oil containing 400\u00a0mg \u03b1-linolenic acid plus 400\u00a0IU vitamin E supplements Anthropometric measurements Weight(kg) 74.1\u2009\u00b1\u200910.7 73.8\u2009\u00b1\u200910.8 \u2212\u20090.3\u2009\u00b1\u20091.1 77.6\u2009\u00b1\u200918.2 77.4\u2009\u00b1\u200918.3 \u2212\u20090.2\u2009\u00b1\u20091.1 Matched for age and phenotypes A and D of PCOS 7 BMI(kg/m 2 ) 28.4\u2009\u00b1\u20094.4 28.2\u2009\u00b1\u20094.6 \u2212\u20090.1\u2009\u00b1\u20090.4 29.0\u2009\u00b1\u20096.5 29.0\u2009\u00b1\u20096.5 \u2212\u20090.1\u2009\u00b1\u20090.4 METs 29.4\u2009\u00b1\u20092.5 29.5\u2009\u00b1\u20092.5 0.1\u2009\u00b1\u20090.8 28.9\u2009\u00b1\u20092.3 28.8\u2009\u00b1\u20092.3 \u2212\u20090.1\u2009\u00b1\u20090.8 Hormonal profile FSH (IU/L) 7.3\u2009\u00b1\u20092.5 7.2\u2009\u00b1\u20092.5 \u2212\u20090.4\u2009\u00b1\u20090.5* 7.9\u2009\u00b1\u20092.8 8.1\u2009\u00b1\u20093.2 0.5\u2009\u00b1\u20090.5* Adjusted for baseline values, age and BMI at baseline LH (IU/L) 11.0\u2009\u00b1\u20098.0 10.5\u2009\u00b1\u20098.9 \u2212\u20091.2\u2009\u00b1\u20091.4* 13.5\u2009\u00b1\u200913.3 11.4\u2009\u00b1\u20097.7 \u2212\u20091.5\u2009\u00b1\u20090.5* oxidative stress TAC (mmol/L) 860.5\u2009\u00b1\u2009101.0 949.9\u2009\u00b1\u2009119.3 60.3\u2009\u00b1\u200919.1* 969.5\u2009\u00b1\u200985.3 975.4\u2009\u00b1\u200998.0 35\u2009\u00b1\u200919.2* GSH (\u00b5mol/L) 525.3\u2009\u00b1\u200984.1 544.8\u2009\u00b1\u200981.3 21.7\u2009\u00b1\u20098.7* 511.8\u2009\u00b1\u200969.1 555.2\u2009\u00b1\u200962.4 41.1\u2009\u00b1\u20098.7* MDA (\u00b5mol/L) 2.9\u2009\u00b1\u20090.6 2.5\u2009\u00b1\u20090.6 \u2212\u20090.2\u2009\u00b1\u20090.1* 2.2\u2009\u00b1\u20090.5 2.2\u2009\u00b1\u20090.5 \u2212\u20090.2\u2009\u00b1\u20090.1* Biochemical profile TG (mg/dL) 122.7\u2009\u00b1\u200961.7 100.6\u2009\u00b1\u200954.0 \u2212\u200921.9\u2009\u00b1\u20094* 120.6\u2009\u00b1\u200959.4 128.3\u2009\u00b1\u200972.6 7.5\u2009\u00b1\u20094* VLDL-C (mg/dL) 24.5\u2009\u00b1\u200912.3 20.1\u2009\u00b1\u200910.8 \u2212\u20094.4\u2009\u00b1\u20090.8* 24.1\u2009\u00b1\u200911.9 25.7\u2009\u00b1\u200914.5 1.5\u2009\u00b1\u20090.8* TC(mg/dL) 181.8\u2009\u00b1\u200928.0 161.5\u2009\u00b1\u200931.4 \u2212\u200918.1\u2009\u00b1\u20093.8* 166.4\u2009\u00b1\u200929.2 178.6\u2009\u00b1\u200929.9 10\u2009\u00b1\u20093.8* LDL-c (mg/dL) 111.1\u2009\u00b1\u200926.5 94.4\u2009\u00b1\u200929.8 \u2212\u200913.3\u2009\u00b1\u20093.7* 92.9\u2009\u00b1\u200925.5 104.8\u2009\u00b1\u200926.3 8.5\u2009\u00b1\u20093.7* HDL-C (mg/dL) 46.2\u2009\u00b1\u200910.0 47.0\u2009\u00b1\u20099.5 0.2\u2009\u00b1\u20090.8* 49.4\u2009\u00b1\u20098.1 48.1\u2009\u00b1\u20099.3 \u2212\u20090.7\u2009\u00b1\u20090.8* TC/HDL-c 4.1\u2009\u00b1\u20091.0 3.6\u2009\u00b1\u20090.9 \u2212\u20090.4\u2009\u00b1\u20090.1* 3.5\u2009\u00b1\u20090.8 3.9\u2009\u00b1\u20091.1 0.3\u2009\u00b1\u20090.1* Ebrahimi, 2017 Iran 18\u201340 (23.8\u2009\u00b1\u20094.6/25.2\u2009\u00b1\u20095.2 ) 68 (34/34) 12 Placebo 1000\u00a0mg omega-3 fatty acids from flaxseed oil containing 400\u00a0mg\u2002\u03b1-Linolenic\u2002acid\u2002plus\u2002400\u00a0IU\u2002vitamin\u2002E\u2002supplements Anthropometric measurements Weight (kg) 72.4\u2009\u00b1\u200910.7 71.9\u2009\u00b1\u200910.7 0 \u2212\u20090.5\u2009\u00b1\u20091.3 75.1\u2009\u00b1\u200918.2 74.8\u2009\u00b1\u200918.3 \u2212\u20090.3\u2009\u00b1\u20091.1 Matched for age, BMI and phenotypes A and D of PCOS 7 BMI(kg/m 2 ) 28.0\u2009\u00b1\u20094.3 27.8\u2009\u00b1\u20094.3 \u2212\u20090.2\u2009\u00b1\u20090.5 28.5\u2009\u00b1\u20096.6 28.3\u2009\u00b1\u20096.7 \u2212\u20090.2\u2009\u00b1\u20090.4 METs 27.0\u2009\u00b1\u20092.3 27.0\u2009\u00b1\u20092.4 0.02\u2009\u00b1\u20090.7 26.8\u2009\u00b1\u20092.1 26.7\u2009\u00b1\u20092.2 \u2212\u20090.1\u2009\u00b1\u20090.7 Biochemical profile FPG(mg/dL) 90.2\u2009\u00b1\u200910.2 87.0\u2009\u00b1\u20098.6 \u2212\u20093.8\u2009\u00b1\u20091.1* 94.8\u2009\u00b1\u20097.4 94.1\u2009\u00b1\u20099.1 \u2212\u20090.05\u2009\u00b1\u20091.1* Adjusted for baseline values, age and BMI at baseline Insulin\u2002(\u03bcIU/mL) 10.8\u2009\u00b1\u20094.8 9.8\u2009\u00b1\u20094.9 \u2212\u20090.8\u2009\u00b1\u20090.9* 9.8\u2009\u00b1\u20095.7 12.5\u2009\u00b1\u20096.6 2.5\u2009\u00b1\u20090.9* HOMA-IR 2.4\u2009\u00b1\u20091.2 2.2\u2009\u00b1\u20091.2 \u2212\u20090.2\u2009\u00b1\u20090.2* 2.3\u2009\u00b1\u20091.4 2.9\u2009\u00b1\u20091.6 0.6\u2009\u00b1\u20090.2* HOMA-B 39.7\u2009\u00b1\u200918.6 35.4\u2009\u00b1\u200919.1 \u2212\u20093.0\u2009\u00b1\u20093.3* 33.7\u2009\u00b1\u200921.4 44.1\u2009\u00b1\u200925.4 9.2\u2009\u00b1\u20093.3* QUICKI 0.34\u2009\u00b1\u20090.02 0.34\u2009\u00b1\u20090.02 0.002\u2009\u00b1\u20090.005* 0.35\u2009\u00b1\u20090.04 0.33\u2009\u00b1\u20090.02 \u2212\u20090.01\u2009\u00b1\u20090.005* Hirsutism mF-G 13.6\u2009\u00b1\u20093.7 13.3\u2009\u00b1\u20093.7 \u2212\u20090.4\u2009\u00b1\u20090.2* 12.2\u2009\u00b1\u20093.5 12.0\u2009\u00b1\u20093.4 \u2212\u20090.3\u2009\u00b1\u20090.2* Hormonal profile Total\u2002testosterone\u2002(ng/mL) 1.2\u2009\u00b1\u20090.9 0.7\u2009\u00b1\u20090.6 \u2212\u20090.4\u2009\u00b1\u20090.08* 1.1\u2009\u00b1\u20090.6 1.0\u2009\u00b1\u20090.6 \u2212\u20090.06\u2009\u00b1\u20090.08* 7 Free\u2002testosterone\u2002(pg/mL) 4.5\u2009\u00b1\u20093.2 3.3\u2009\u00b1\u20092.4 \u2212\u20091.1\u2009\u00b1\u20090.3* 3.9\u2009\u00b1\u20092.7 3.7\u2009\u00b1\u20092.3 \u2212\u20090.4\u2009\u00b1\u20090.3* SHBG (nmol/L) 37.5\u2009\u00b1\u200915.9 44.1\u2009\u00b1\u200921.3 6.9\u2009\u00b1\u20092.4* 39.1\u2009\u00b1\u200915.0 44.9\u2009\u00b1\u200916.9 5.5\u2009\u00b1\u20092.4* FAI 0.14\u2009\u00b1\u20090.13 0.09\u2009\u00b1\u20090.11 \u2212\u20090.04\u2009\u00b1\u20090.01* 0.12\u2009\u00b1\u20090.17 0.08\u2009\u00b1\u20090.05 \u2212\u20090.04\u2009\u00b1\u20090.01* DHEAS 4.5\u2009\u00b1\u20092.3 3.5\u2009\u00b1\u20092.0 \u2212\u20091.2\u2009\u00b1\u20090.2* 5.2\u2009\u00b1\u20091.9 4.3\u2009\u00b1\u20091.5 \u2212\u20090.7\u2009\u00b1\u20090.2* Izadi, 2019 Iran 20\u201340 (27.18\u2009\u00b1\u20095.77/ 26.0\u2009\u00b1\u20094.53) 43 (22/21) 8 Placebo 400\u00a0IU\u2002vitamin\u2002E Anthropometric measurements BMI(kg/m 2 ) 29.28\u2009\u00b1\u20094.24 28.92\u2009\u00b1\u20094.23 \u20120.37 (\u20120.60, \u20120.14)** 28.73\u2009\u00b1\u20093.39 28.74\u2009\u00b1\u20092.9 0.01 (\u20120.23, 0.25)** \u2013 7 WC (cm) 95.00\u2009\u00b1\u200910.82 92.18\u2009\u00b1\u200910.94 \u20122.81, (\u20123.47, \u20122.15)** 89.33\u2009\u00b1\u20097.97 88.43\u2009\u00b1\u20098.04 \u20120.89, (\u20121.57, \u20120.21)** Biochemical profile TG (mg/dL) 111.68\u2009\u00b1\u200944.41 105.18\u2009\u00b1\u20098.22 \u2212\u20096.48 (\u2212\u20099.31,\u2009\u2212\u20093.66)** 112.86\u2009\u00b1\u200942.27 112.09\u2009\u00b1\u20099.09 \u2212\u20090.99 (\u2212\u20093.89, 1.90)** Adjusted for baseline levels, age, physical activity, dietary intake of energy and vitamin E TC (mg/dL) 163.41\u2009\u00b1\u200921.86 159.00\u2009\u00b1\u200918.96 \u2212\u20094.07 (\u2212\u20099.14, 1.00)** 157.43\u2009\u00b1\u200918.46 159.67\u2009\u00b1\u200922.87 2.37 (\u2212\u20092.84, 7.57)** LDL-C (mg/dL) 82.53\u2009\u00b1\u200920.51 78.10\u2009\u00b1\u200919.83 \u2212\u20094.02 (\u2212\u20099.60, 1.54)** 79.57\u2009\u00b1\u200924.17 82.53\u2009\u00b1\u200922.84 3.07 (\u2212\u20092.64, 8.78)** HDL-C (mg/dL) 58.54\u2009\u00b1\u20099.21 59.86\u2009\u00b1\u20098.45 1.24 (\u2212\u20090.56, 3.05)** 55.28\u2009\u00b1\u200911.94 54.71\u2009\u00b1\u20099.81 \u2212\u20090.5 (\u2212\u20092.36, 1.35)** Non-HDL-C (mg/dL) 104.86\u2009\u00b1\u200922.29 99.14\u2009\u00b1\u200919.78 \u2212\u20095.32 (\u2212\u200910.94, 0.31)** 102.14\u2009\u00b1\u200924.39 104.95\u2009\u00b1\u200924.79 2.87 (\u2212\u20092.90, 8.64)** Jamilian, 2019 Iran 18\u201340 (29.2\u2009\u00b1\u20097.2/28.3\u2009\u00b1\u20093.8 ) 60 (30/30) 12w Placebo 250\u00a0mg/day magnesium plus 400\u00a0mg/ day vitamin E supplements Anthropometrics measurements Weight(kg) 66.7\u2009\u00b1\u20099.5 66.6\u2009\u00b1\u20099.5 \u20130.1\u2009\u00b1\u20090.3 67.8\u2009\u00b1\u200910.9 67.7\u2009\u00b1\u200911.1 \u20130.1\u2009\u00b1\u20090.8 \u2013 7 BMI(kg/m 2 ) 25.5\u2009\u00b1\u20093.5 25.5\u2009\u00b1\u20093.3 \u20130.03\u2009\u00b1\u20090.1 26.0\u2009\u00b1\u20094.7 26.0\u2009\u00b1\u20094.7 \u20130.05\u2009\u00b1\u20090.3 Biochemical profile FPG(mg/dl) 92.1\u2009\u00b1\u200912.2 90.9\u2009\u00b1\u200911.9 \u20131.5\u2009\u00b1\u20091.0* 93.7\u2009\u00b1\u20095.8 94.4\u2009\u00b1\u20096.5 1.0\u2009\u00b1\u20091.0* Adjusted for baseline values\u2009+\u2009age and baseline BMI TG (mg/dl) 125.0\u2009\u00b1\u200953.0 110.0\u2009\u00b1\u200955.0 \u2212\u200915.1\u2009\u00b1\u20094.4* 128.1\u2009\u00b1\u200960.6 134.7\u2009\u00b1\u200968.9 6.8\u2009\u00b1\u20094.4* VLDL-C (mg/dl) 25.0\u2009\u00b1\u200910.6 22.0\u2009\u00b1\u200911.0 \u20133.0\u2009\u00b1\u20099.9* 25.6\u2009\u00b1\u200912.1 26.9\u2009\u00b1\u200913.8 1.3\u2009\u00b1\u20090.9* TC(mg/dl) 181.6\u2009\u00b1\u200940.4 174.5\u2009\u00b1\u200932.2 \u20137.2\u2009\u00b1\u20094.4* 185.0\u2009\u00b1\u200934.4 193.2\u2009\u00b1\u200933.7 8.3\u2009\u00b1\u20094.4* LDL-C (mg/dl) 104.5\u2009\u00b1\u200936.0 101.4\u2009\u00b1\u200930.4 \u20132.7\u2009\u00b1\u20094.6* 106.2\u2009\u00b1\u200937.1 114.2\u2009\u00b1\u200938.9 7.6\u2009\u00b1\u20094.6* HDL-C (mg/dl) 52.1\u2009\u00b1\u200910.1 51.1\u2009\u00b1\u20098.6 \u20131.1\u2009\u00b1\u20091.2* 53.1\u2009\u00b1\u20099.3 52.0\u2009\u00b1\u200910.9 \u20131.0\u2009\u00b1\u20091.2* TC/HDL-C ratio \u2013 \u2013 \u20130.05\u2009\u00b1\u20090.1* \u2013 \u2013 0.3\u2009\u00b1\u20090.1* Insulin\u2002(\u03bcIU/mL) 13.4\u2009\u00b1\u20095.8 12.3\u2009\u00b1\u20095.0 \u20131.0\u2009\u00b1\u20090.5* 12.2\u2009\u00b1\u20095.1 13.9\u2009\u00b1\u20094.5 1.5\u2009\u00b1\u20090.5* HOMA-IR 3.0\u2009\u00b1\u20091.4 2.8\u2009\u00b1\u20091.2 \u2212\u20090.2\u2009\u00b1\u20090.1* 2.8\u2009\u00b1\u20091.2 3.2\u2009\u00b1\u20091.1 0.4\u2009\u00b1\u20090.1* QUICKI 0.32\u2009\u00b1\u20090.01 0.33\u2009\u00b1\u20090.01 0.003\u2009\u00b1\u20090.003* 0.33\u2009\u00b1\u20090.02 0.32\u2009\u00b1\u20090.01 \u2212\u20090.008\u2009\u00b1\u20090.003* Izadi, 2019 Iran 20\u201340 (27.18\u2009\u00b1\u20095.77/ 26.0\u2009\u00b1\u20094.53) 43 (22/21) 8 Placebo 400\u00a0IU\u2002vitamin\u2002E Anthropometric measurements Weight (kg) 76.95\u2009\u00b1\u200910.61 75.96\u2009\u00b1\u200910.3 \u2212\u20091.33 (\u2212\u20090.4 to 2.29)** 73.23\u2009\u00b1\u20097.58 73.29\u2009\u00b1\u20097.3 0.15 (\u2212\u20090.49 to 0.9)** \u2013 7 Biochemical profile FBS(mg/dl) 85.50\u2009\u00b1\u200920.28 81.18\u2009\u00b1\u200910.28 4.32 (0.85 to 7.67)** 17.95\u2009\u00b1\u20099.25 80.57\u2009\u00b1\u20098.96 \u2212\u20090.10 (\u2212\u20093.69 to 3.48)** Adjusted for baseline values, age, BMI, and physical activity Insulin\u2002(mIU/L) 13.72\u2009\u00b1\u20095.92 11.44\u2009\u00b1\u20094.57 2.26 (0.36 to 4.16)** 13.47\u2009\u00b1\u20099.73 12.47\u2009\u00b1\u20097.73 0.89 (1.14 to 2.78)** HOMA-IR 2.80\u2009\u00b1\u20091.17 2.35\u2009\u00b1\u20091.01 0.45 (0.02 to 0.87)** 2.73\u2009\u00b1\u20092.12 2.55\u2009\u00b1\u20091.70 0.16 (\u2212\u20090.28 to 0.60)** Hormonal profile Total\u2002testosterone\u2002(ng/ml) 1.16\u2009\u00b1\u20090.40 0.84\u2009\u00b1\u20090.23 0.32 (0.17 to 0.46)** 1.33\u2009\u00b1\u20090.35 1.47\u2009\u00b1\u20090.39 \u2212\u20090.13 (\u2212\u20090.28 to 0.02)** SHBG 38.00 (25.32 to 72.50)*** 54.10 (31.50 to 66.20)*** \u2212\u20095.93 (\u2212\u200916.08 to 4.23)** 42.30 (25.20 to 56.80)*** 40.80 (31.00 to 44.50)*** 1.05 (\u2212\u20099.43 to 11.52)** FAI 3.08 (1.57 to 8.13)*** 1.66 (1.14 to 2.92)*** 1.39 (0.47 to 2.32)** 2.80 (2.02 to 4.99)*** 3.53 (2.57 to 5.12)*** 0.42 (\u2212\u20090.91 to 0.99)** LH(mIU/ml) 11.15 (7.30 to 17.05)*** 7.25 (6.35 to 15.00)*** 4.88 (2.72 to 7.4)** 8.40 (5.200 to 17.85)*** 10.80 (6.70 to 17.95)*** \u2212\u20090.49 (\u2212\u20092.72 to 1.73)** FSH (mIU/mL) 5.90 (5.27 to 6.77)*** 5.10 (3.75 to 6.27)*** 0.63 (\u2212\u20090.46 to 1.72)** 7.30 (3.70 to 7.65)*** 5.90 (4.80 to 7.10)*** 0.21 (\u2212\u20090.98 to 1.4)** Progesterone (ng/mL) 1.80\u2009\u00b1\u20090.86 2.46\u2009\u00b1\u20091.02 \u2212\u20090.0 (\u2212\u20091.06 to\u2009\u2212\u20090.27)** 1.62\u2009\u00b1\u20090.99 1.60\u2009\u00b1\u20091.12 \u2212\u20090.02 (\u2212\u20090.45 to 0.41)** Estradiol (pg/mL) 85.45\u2009\u00b1\u200917.79 99.66\u2009\u00b1\u200923.01 \u2212\u200913.92 (\u2212\u200934.25 to 6.42)** 74.43\u2009\u00b1\u200917.95 71.09\u2009\u00b1\u200912.38 1.74 (\u2212\u200920.36 to 23.85)** Talari, 2018 Iran 18\u201340 60 (30/30) 12 Placebo 1000\u00a0mg omega-3 plus 400\u00a0IU vitamin E supplements Inflammatory markers hs-CRP (ng/mL) 2877.9\u2009\u00b1\u20092095.5 2487.3\u2009\u00b1\u20091673.1 \u2212\u2009360.2\u2009\u00b1\u2009140.1 2646.7\u2009\u00b1\u20091492.3 2883.7\u2009\u00b1\u20091488.9 206.6\u2009\u00b1\u2009140.1 Adjusted for baseline values, age, BMI at baseline 6 NO(\u03bcmol/L) 49.6\u2009\u00b1\u20092.3 51.3\u2009\u00b1\u20094.7 1.8\u2009\u00b1\u20090.7 46.0\u2009\u00b1\u20096.0 46.1\u2009\u00b1\u20095.9 \u2212\u20090.05\u2009\u00b1\u20090.7 Shokrpour , 2019 Iran 18\u201340 (27.2\u2009\u00b1\u20097.1/26.0\u2009\u00b1\u20093.7) 60 (30/30) 12w Placebo 250\u00a0mg/day magnesium plus 400\u00a0mg/day vitamin E supplements Anthropometric measurements Weight (kg) 69.4\u2009\u00b1\u200910.7 69.2\u2009\u00b1\u200910.6 \u2212\u20090.2\u2009\u00b1\u20090.3 70.9\u2009\u00b1\u200910.3 70.7\u2009\u00b1\u200910.4 \u2212\u20090.1\u2009\u00b1\u20090.6 Matched for age and BMI 7 BMI(kg/m 2 ) 27.1\u2009\u00b1\u20094.2 27.0\u2009\u00b1\u20094.1 \u2212\u20090.1\u2009\u00b1\u20090.1 27.9\u2009\u00b1\u20094.2 27.8\u2009\u00b1\u20094.2 \u2212\u20090.1\u2009\u00b1\u20090.2 Hirsutism mF-G 14.9\u2009\u00b1\u20092.9 14.6\u2009\u00b1\u20092.5 \u2013 13.8\u2009\u00b1\u20093.8 13.8\u2009\u00b1\u20093.8 \u2013 \u2013 Inflammatory markers hs-CRP (ng/mL) 3.7\u2009\u00b1\u20091.9 3.1\u2009\u00b1\u20091.7 \u2013 3.5\u2009\u00b1\u20091.5 3.7\u2009\u00b1\u20091.5 \u2013 NO(\u03bcmol/L) 34.4\u2009\u00b1\u20092.3 38.7\u2009\u00b1\u20094.0 \u2013 36.6\u2009\u00b1\u20095.6 37.0\u2009\u00b1\u20095.8 \u2013 Oxidative stress TAC (mmol/l) 522.4\u2009\u00b1\u200930.6 590.7\u2009\u00b1\u200952.2 \u2013 513.7\u2009\u00b1\u200981.7 514.5\u2009\u00b1\u200977.3 \u2013 GSH (\u03bcmol/L) 508.1\u2009\u00b1\u200969.1 519.4\u2009\u00b1\u200947.7 \u2013 481.1\u2009\u00b1\u2009101.2 483.8\u2009\u00b1\u200994.2 \u2013 MDA (\u03bcmol/L) 2.7\u2009\u00b1\u20090.2 2.6\u2009\u00b1\u20090.2 \u2013 2.4\u2009\u00b1\u20090.5 2.5\u2009\u00b1\u20090.5 \u2013 Hormonal profile Total\u2002testosterone\u2002(ng/ml) 1.4\u2009\u00b1\u20090.8 1.3\u2009\u00b1\u20090.7 \u2013 1.2\u2009\u00b1\u20090.5 1.2\u2009\u00b1\u20090.6 \u2013 SHBG )nmol/l) 51.4\u2009\u00b1\u200926.4 62.9\u2009\u00b1\u200936.3 \u2013 48.5\u2009\u00b1\u200915.1 49.2\u2009\u00b1\u200915.2 \u2013 FAI 0.15\u2009\u00b1\u20090.16 0.11\u2009\u00b1\u20090.11 \u2013 0.09\u2009\u00b1\u20090.05 0.09\u2009\u00b1\u20090.05 \u2013 Sadeghi, 2019 Iran 18\u201340 (26.67\u2009\u00b1\u20093.35 /26.98\u2009\u00b1\u20093.78) 62 (32/30) 8w Placebo 2\u00a0g of omega-3 plus 400\u00a0IU of vitamin E Oxidative stress TAC(mg/dl) 12.42\u2009\u00b1\u20091.95 13.58\u2009\u00b1\u20092.06 1.15\u2009\u00b1\u20090.93 12.22\u2009\u00b1\u20091.91 12.16\u2009\u00b1\u20091.96 \u2212\u20090.6\u2009\u00b1\u20090.72 \u2013 6 Catalase (IU/L) 10.18\u2009\u00b1\u20091.27 12.01\u2009\u00b1\u20091.26 1.19\u2009\u00b1\u20091.06 11.14\u2009\u00b1\u20091.11 11.26\u2009\u00b1\u20091.15 0.12\u2009\u00b1\u20090.36 GLU (\u03bcmol/L) 10.65\u2009\u00b1\u20092.57 12.15\u2009\u00b1\u20092.66 1.5\u2009\u00b1\u20091.06 10.77\u2009\u00b1\u20092.53 11.00\u2009\u00b1\u20092.65 0.23\u2009\u00b1\u20091.43 MDA (\u03bcmol/L) 1.76\u2009\u00b1\u20090.29 1.42\u2009\u00b1\u20090.26 \u2212\u20090.34\u2009\u00b1\u20090.32 1.38\u2009\u00b1\u20090.26 1.95\u2009\u00b1\u20092.23 0.57\u2009\u00b1\u20092.20 Shirazi, 2019 Iran 20\u201340 (27.18\u2009\u00b1\u20095.77 /26.0\u2009\u00b1\u20094.53) 43 (22/21) 8w Placebo 400\u00a0IU/day vitamin E -as alpha tocopheryl acetate Anthropometric measurements Weight (kg) 76.95\u2009\u00b1\u200910.61 75.96\u2009\u00b1\u200910.3 \u2013 73.23\u2009\u00b1\u20097.58 73.29\u2009\u00b1\u20097.3 \u2013 Matched for age and BMI 7 BMI(kg/m 2 ) 29.45\u2009\u00b1\u20095.35 29.07\u2009\u00b1\u20095.16 \u2013 28.80\u2009\u00b1\u20093.71 28.83\u2009\u00b1\u20093.70 \u2013"
        }
    ],
    "images": [
        {
            "caption": "Flow chart of the systematic search and study selection."
        },
        {
            "caption": "Forest plots of the effect of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on lipid profile. If the diamond does not touch the vertical line (or the line of null effect), the overall effect is statistically significant. Significant reductions were found in serum levels of TG (WMD:\u2009\u2212\u200918.27\u00a0mg/dL, 95% CI\u2009\u2212\u200934.68 to\u2009\u2212\u20091.87), VLDL (WMD:\u2009\u2212\u20095.88\u00a0mg/dL, 95% CI\u2009\u2212\u20098.08 to\u2009\u2212\u20093.68), LDL-c (WMD:\u2009\u2212\u200912.84\u00a0mg/dL, 95% CI\u2009\u2212\u200922.15 to\u2009\u2212\u20093.52), TC (WMD:\u2009\u2212\u200916.30\u00a0mg/dL, 95% CI\u2009\u2212\u200929.74 to\u2009\u2212\u20092.86) and TC /HDL-c ratio (WMD:\u2009\u2212\u20090.52, 95% CI\u2009\u2212\u20090.87 to\u2009\u2212\u20090.18) in PCOS patients after vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation in comparison to placebo."
        },
        {
            "caption": "Forest plots of the effect of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on biomarkers of inflammation and oxidative stress. If the diamond does not touch the vertical line (or the line of null effect), the overall effect is statistically significant. A significant decrease in serum level of hs-CRP (WMD\u2009\u2212\u20090.60\u00a0ng/mL, 95% CI\u2009\u2212\u20090.77 to\u2009\u2212\u20090.44) and a significant increase in the serum level of NO (WMD: 2.79\u00a0\u00b5mol/L, 95% CI 0.79\u20134.79) were found in PCOS patients after vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation in comparison to placebo."
        },
        {
            "caption": "Forest plots of the effect of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on glycemic indexes. If the diamond does not touch the vertical line (or the line of null effect), the overall effect is statistically significant. No significant effects of vitamin E supplementation or vitamin E supplementation plus omega-3 or magnesium on glycemic indices were found in PCOS patients."
        },
        {
            "caption": "Forest plots of the effect of vitamin E supplementation or vitamin E along with omega-3 or magnesium supplementation on hormonal profile. If the diamond does not touch the vertical line (or the line of null effect), the overall effect is statistically significant. No significant effect of vitamin E supplementation or vitamin E plus omega-3 or magnesium supplementation on hormonal profile was found in PCOS patients."
        }
    ]
}